Company Analysis
Sign in

Redhill Biopharma Ltd. (RDHL)

Nasdaq: RDHL · Pharmaceutical Preparations · Tel Aviv, IL · filing with the SEC since 2012
Full chart Alerts Compare
Grade3.9
◀ Past 5.1● Present 3.5▶ Future 3.6
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2024, as filed
Revenue$8.0M+23.2%
Net income-$8.3M-134.6%
Earnings per share$0.00-100.0%
Operating cash flow-$9.4M+73.8%
Cash$4.6M-17.1%
Debtn/a
Shareholders’ equity-$4.7M-326.3%
Shares, diluted12.32B+375.6%
Return on equityn/a
The recordfrom its filings
Filings in 202660
Newest filingNov 2 · 6-K
Annual reportApr 27, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted42
Filer categoryNon-accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
15161718192021222324
As filed, in USD. Nothing here is a forecast.

News

Oct 13, 2026 · SEC EDGAR · Form 424B5
Shelf offering
Open the filing on sec.gov
Oct 6, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton RDHL · research, not advice